Magic Mushroom-Derived drug enters final trial for depression
Symptom relief
Recruiting now
This Phase 3 study tests whether CYB003, a psilocin analog (related to the active ingredient in magic mushrooms), can safely reduce depression symptoms in 330 adults with major depressive disorder. Participants receive either one of two doses of CYB003 or a placebo, along with ps…
Phase: PHASE3 • Sponsor: Cybin IRL Limited • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC